Liraglutide for the treatment of type 2 diabetes: A clinical update

American Journal of Therapeutics

Volumn 20, Issue 2, 2013, Pages 178-188

  Peters, Kyle R ^a,b  

^a Siouxland Community Health Center   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

GLP 1 receptor agonist; Glucagon like peptide 1 (GLP 1) analog; Incretins; Liraglutide; NN2211; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; EXENDIN 4; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; TASPOGLUTIDE;

ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; DIABETES CONTROL; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THYROID HYPERPLASIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84875213764     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182204c16     Document Type: Article

References (61)

1. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144: 465-474
2. Tibaldi J, Rakel RE. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract. 2007;61:633-644
3. Tibaldi J. Actions of insulin beyond glycemic control: A perspective on insulin detemir. Adv Ther. 2007;24:868-882
4. Drucker DJ, Nauck MA. The incretin system: Glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705
5. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220-224
6. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol. 2004;286:R269-R272
7. Byetta (exenatide) injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc; September, 2010
8. Victoza (liraglutide [rDNA origin] injection), solution for subcutaneous use [prescribing information]. Princeton, NJ: Novo Nordisk Inc; December, 2010
9. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-Acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202
10. Watson E, Jonker DM, Jacobsen LV, et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50:886-894
11. Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898-905
12. Davidson JA, Brett J, Falahati A, et al. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract. 2010;1-31
13. Mä nttäri M, Tenkanen V, Alikoskin T, et al. Antihypertensive therapy in dyslipidemic men: Effects on coronary heart disease incidence and total mortality. Hypertension. 1995;25:47-52
14. Damholt B, Golor G, Wierich W, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46:635-641
15. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70:807-814
16. Morrow L, Hompesch M, Guthrie H, et al. Co-Administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13:75-80
17. Neumiller JJ, Campbell RK. Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43:1433-1444
18. Courreges JP. Meta analyse des etudes LEAD (Liraglutide Effects & Action on Diabetes) Diabetes Metab. 2010; 36(suppl 1):A36. Abstract PO32
19. Garber AJ. Glucagon-like peptide-1-based therapies: New developments and emerging data. Diabetes Obes Metab. 2008;10:22-36
20. Marre M, Shaw J, Brandle M, et al. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278
21. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90
22. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-Treatment trial. Lancet. 2009;373:473-481
23. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met + TZD). Diabetes Care. 2009;32: 1224-1230
24. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: A randomised controlled trial (LEAD-5 met + SU). Diabetologia. 2009;52:2046-2055
25. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47
26. Buse JB, Sesti G, Schmidt WE, et al. Switching to oncedaily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303
27. Gallwitz B, Vaag A, Falahati A, et al. Adding liraglutide to oral antidiabetic drug therapy: Onset of treatment effects over time. Int J Clin Pract. 2010;64:267-276
28. Garber A, Matthews D, Holst J, et al. The effect of diabetes duration on the response to liraglutide and glimepiride in type 2 diabetes. Diabetes. 2010;59(suppl 1):A197. Abstract 722-P.
29. Charbonnel B, Thiriet CM, Guerci B. Reaching a clinically relevant composite endpoint of HbA1c target, 7% -no hypoglycaemia -no weight gain, with liraglutide vs. other T2D therapies. Diabetes. 2010;59(Suppl 1):A162. Abstract 593-P.
30. Garber A, Henry RR, Ratner R, et al. Liraglutide, a oncedaily human GLP-1 analogue, provides sustained improvements in glycaemic control and weight for two years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13:348-356
31. Frid A, Hermansen K, Nauck M, et al. Long-Term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data. Presented at: European Association for the Study of Diabetes 45th Annual Meeting September 27-October 1, 2009; Vienna, Austria. Abstract 3-OR.
32. Matthews D, Vilsboll T, Courreges J-P, et al. Liraglutide improves beta-cell function as assessed by HOMA-B and proinsulin: Insulin ratio: Neta-Analysis of 6 clinical trials. Diabetes. 2010;59(suppl 1):A401. Abstract 1513-P.
33. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009;374: 1606-1616
34. Jendle J, Nauck MA, Matthews DR, et al.Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-1172
35. Russell-Jones D, Sesti G, Garber A, et al. Liraglutide causes reductions in body weight both in patients with and without gastrointestinal side effects. Diabetes. 2010; 59(Suppl 1):A493. Abstract 1886-P
36. Zinman B, Colagiuri S, Madsbad S, et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: Neta-Analysis of six phase 3 trials. Diabetes. 2010;59(Suppl 1):A495. Abstract 1894-P.
37. Bakris GL,Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis. 2000;36:646-661
38. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860
39. Madsbad S, Fonseca V, Plutzky J, et al. Meta-Analysis of the effect of liraglutide, a once-daily human GLP-1 analogue, on systolic blood pressure in type 2 diabetes. Diabet Med. 2010;27(suppl 1):77. Abstract P135
40. Fonseca V, Plutzky J,Montanya E, et al. Liraglutide, a oncedaily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment. Diabetes. 2010;59(Suppl 1):A79. Abstract 296-OR.
41. Henry R, Fonseca V, Tabanera YP. Liraglutide, a once-daily human GLP-1 analog, reduces systolic blood pressure with minimal impact from weight loss in subjects with type 2 diabetes. Presented at: 92nd Annual Endocrine Society Meeting, June 19-22, 2010; San Diego, CA. Abstract P3-514
42. Fonseca VA, Henry RR, Tabanera Y, et al. In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss. Diabetologia. 2010;53(suppl 1): S510. Abstract 1292
43. Gough S, Madsbad S, Jensen K, et al. Liraglutide is associated with reduced rates of hypoglycemic events versus glimepiride when achieving target HbA1c. Diabetes. 2010;59(suppl 1):A208-A209. Abstract 764-P.
44. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-The FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362:774-777
45. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009;32:834-838
46. Garber JR, Braverman L. Liraglutide statement. American Association of Clinical Endocrinologists; March 17, 2010; Jacksonville, F.L.
47. Knudsen LB, Madsen LW, Andersen S, et al. Glucagonlike peptide-1 receptor agonists activate rodent thyroid Ccells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473-1486
48. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96:853-860
49. Russell-Jones D, Foster C. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137-140
50. Garber A, Marre M, Nauck M. The efficacy of liraglutide is not impacted in subjects positive for anti-liraglutide antibodies: A pooled analysis. Presented at: American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress, April 21-25, 2010; Boston, MA. Abstract 255
51. Buse J, Montanya E, Brett J, et al. Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Diabetes. 2010; 59(suppl 1):A184-A185. Abstract 676-P.
52. Bode BW, Testa MA, Magwire M, et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: Results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:604-612
53. Schmidt WE, Christiansen JS, Hammer M, et al. Patient reported outcomes are superior in patients with type 2 diabetes (T2D) treated with liraglutide as compared to exenatide, when added tometformin, sulfonylurea or both. Diabetes. 2009;58(suppl 1):A483-A484. Abstract 1880-P.
54. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456
55. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643
56. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, andmetformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;1979-1987
57. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10:959-969
58. Garber A, Thomsen A, Falahati A, et al. Liraglutide promoted more weight loss with improved glycemic control than sitagliptin. Diabetes. 2010;59(suppl 1):A190. Abstract 697-P.
59. Pratley R, Nauck M, Bailey T, et al. Liraglutide treatment for 1 year offers sustained and more effective glycemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes. Presented at: 70th American Diabetes Association Scientific Sessions, June 25-29, 2010; Orlando, FL. Abstract 16-LB.
60. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203
61. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15:540-559